funapide

Funapide is a small molecule analgesic developed for the treatment of various chronic pain conditions, including osteoarthritis, neuropathic pain, postherpetic neuralgia, erythromelalgia, and dental pain. It acts as a selective blocker of voltage-gated sodium channels Nav1.7 (SCN9A) and Nav1.8, which are crucial in the generation and propagation of pain signals in peripheral neurons. By inhibiting these channels, funapide reduces neuronal excitability and decreases pain perception[3][4][6]. The drug was originally developed by Xenon Pharmaceuticals and has been investigated in both oral and topical formulations[4]. It received orphan drug designation from the FDA for erythromelalgia but development was discontinued after phase II trials failed to meet efficacy endpoints for postherpetic neuralgia[3][5].

Other names

Funapide [INN]Funapide [USAN](+)-Funapide